A Phase II Study of Everolimus (RAD001) for Children with Neurofibromatosis Type I and Chemotherapy-Refractory Radiographic Progressive Low-Grade

Grant

Date/time Interval

  • February 7, 2013 - February 6, 2018
  • Total Award Amount

  • 84503.00
  • Direct Costs

  • 76821.00
  • Sponsor Award Id

  • Contributor

  • Cutter, Gary   Investigator  
  • Korf M.D., Ph.D., Bruce   Principal Investigator